News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
New dosing options for PD-1 inhibitor in first and second-line esophageal squamous cell carcinoma – BeOne Medicines
BeOne Medicines/Instagram
Apr 24, 2025, 11:06

New dosing options for PD-1 inhibitor in first and second-line esophageal squamous cell carcinoma – BeOne Medicines

BeOne Medicines shared a post on LinkedIn:

“The FDA has approved new dosing options for our PD-1 inhibitor in both first- and second-line esophageal squamous cell carcinoma (ESCC) and first-line gastric cancer, providing more flexibility for pairing our immunotherapy with the most common chemotherapy regimens.

This approval reinforces our dedication to patients in the U.S. living with upper GI cancers—helping to expand access to personalized treatment approaches and supporting providers in delivering care that fits the unique needs of each patient.”

New dosing options for PD-1 inhibitor in first and second-line esophageal squamous cell carcinoma - BeOne Medicines

BeOne Medicines cancer chemotherapy ESCC esophageal squamous cell carcinoma FDA fight against cancer GI cancers Global fight against cancer immunotherapy OncoDaily Oncology PD-1 inhibitor
Special Coverage
Blog
Aug 2, 2025, 08:22
Significant Event to Advance Equitable Cancer Care in Kenya - Kenyan Network of Cancer Organizations
Blog
Aug 2, 2025, 08:07
Rami Manochakian: "Era of hope" for Patients with Lung Cancer
Blog
Aug 2, 2025, 08:06
Chalothorn “Sai” Wannaphut: Racial Disparities in Non–Small Cell Lung Cancer Survival Outcomes
Blog
Aug 2, 2025, 07:52
Allison Rosen: Grateful to Contribute to QI in Peds/AYA Oncology Survivorship Care
Blog
Aug 2, 2025, 07:04
Catharine Young: Making Profound Impact on the Lives of Cancer Patients in LMICs
Blog
Aug 2, 2025, 06:54
New Drugs and the Impact of Artificial Intelligence - ESO
Blog
Aug 2, 2025, 06:37
Post-Traumatic Growth in Cancer Patients - CancerWorld
Drugs
Aug 2, 2025, 06:29
Telisotuzumab vedotin (Emrelis) Updates 2025: Uses in Cancer, Dosage, Side Effects, Expectations, and More
Oncolibrary
Aug 2, 2025, 05:52
Immigration and Cancer Outcomes: Bridging the Gap in Healthcare Access
Insight
Aug 2, 2025, 00:36
Elizabeth Smyth: Review on a Key Emerging Biomarker in Gastric and Gastroesophageal Cancer
Blog
Aug 2, 2025, 00:00
Maryam Lustberg: Discussing PCPs vs Oncologists
Blog
Aug 1, 2025, 23:23
Big Changes are Coming to How Cancer Research Gets Funded - Fight Colorectal Cancer